| AD | anxiety disorders |
| BBB | blood–brain barrier |
| BDNF CTIS |
brain-derived neurotrophic factor Clinical Trials Information System |
| CTA | Clinical Trial Application |
| DMN | Default Mode Network |
| DMT | N,N-Dimethyltryptamine |
| EMA | European Medicines Agency |
| EU | European Union |
| EU CTR | EU Clinical Trials Register |
| EUDA | European Union Drugs Agency |
| FDA | Food and Drug Administration |
| IRB | Institutional Review Board |
| LSD | lysergic acid diethylamide |
| MAPS | Multidisciplinary Association for Psychedelic Studies |
| MD | major depression |
| MDMA | 3,4-methylenedioxy-N-methylamphetamine |
| OCD | obsessive-compulsive disorders |
| PAREA | Psychedelics Access and Research European Alliance |
| PTSD | post-traumatic stress disorder |
| RDD | recurrent depressive disorder |
| TRD | treatment-resistant major depression |
| USA/US | United States of America |
| WHO | World Health Organisation |